What is the treatment of choice for acute bronchospasm in asthma?

Inhaled short-acting beta-agonists (SABAs) are considered the treatment of choice for acute bronchospasm in asthma due to their rapid onset and effectiveness in relieving acute symptoms. These medications work by stimulating beta-2 adrenergic receptors in the bronchial smooth muscle, leading to relaxation of the airways. This effect occurs within minutes, making them particularly useful during an asthma attack when immediate relief is required.

SABAs, such as albuterol, quickly alleviate symptoms such as wheezing, coughing, shortness of breath, and chest tightness. Their ability to provide prompt bronchodilation is essential in emergency situations or when a patient experiences worsening asthma control.

Other treatment options, such as oral corticosteroids, LABAs, and leukotriene receptor antagonists, have specific roles in asthma management but are not appropriate for immediate relief of acute bronchospasm. Oral corticosteroids are typically used for longer-term control and to manage inflammation rather than providing rapid symptom relief. LABAs are used in conjunction with inhaled corticosteroids for asthma maintenance but are not indicated as rescue medications. Leukotriene receptor antagonists are more useful for ongoing asthma management and preventing symptoms, rather than treating acute episodes. Thus, for immediate intervention in